Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib and Ibrutinib in Mantle Cell Lymphoma
NCT03877055Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copanlisib and ibrutinib in mantle cell lymphoma (MCL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Complete Response at 2 years. Started Mar 2019; status: completed.
02
Drugs
copanlisibibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03877055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03877055.